Crexendo Insider Filing: Chief Strategy Officer Reports RSU Grants, Withholdings
Rhea-AI Filing Summary
Anand Buch, Chief Strategy Officer of Crexendo, Inc. (CXDO), reported restricted stock unit (RSU) activity and related share withholdings on September 4–5, 2025. The filing shows grants of 2,083 RSUs on 09/04/2025 and 4,167 RSUs on 09/05/2025, each with $0 exercise price and vesting in equal quarterly installments over 12 quarters subject to continued employment. The company withheld 1,218 shares on 09/04/2025 and 1,959 shares on 09/05/2025 to cover payroll taxes using closing prices of $6.49 and $6.59. Following these transactions, Mr. Buch beneficially owned 563,042 shares of common stock and 25,000 RSUs.
Positive
- No open-market sales reported; withheld shares were used solely to satisfy payroll taxes, not a sale by the reporting person
- Long-term vesting schedule (quarterly over 12 quarters) aligns executive compensation with ongoing performance
Negative
- None.
Insights
TL;DR: Routine equity compensation and tax-withholding activity; increases in vested alignment with management but no open-market sales.
The Form 4 documents RSU grants and tax-withholdings rather than discretionary market sales. The grants vest quarterly over three years, creating longer-term alignment of the Chief Strategy Officer with shareholder outcomes. Withholdings of 1,218 and 1,959 shares were executed to satisfy payroll taxes at closing prices of $6.49 and $6.59, respectively. The reporting shows total beneficial ownership of 563,042 common shares and 25,000 RSUs following the reported entries, indicating continued concentrated insider ownership but no disposition that would signal liquidity-taking.
TL;DR: Standard compensation disclosure; vesting schedule and tax-withholding are consistent with routine executive equity awards.
The filing discloses conditional RSUs that vest in equal quarterly installments over 12 quarters, subject to service. Withholding of shares to satisfy payroll taxes is explicitly noted as not representing a sale by the reporting person. These details conform to typical executive equity compensation practices and provide transparency on dilution timing and insider alignment. No changes in control, option exercises for cash, or market sales by the reporting person are reported.